Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Biovitrum AB acquires the pharmaceutical company Arexis AB
Mandate

Biovitrum AB acquires the pharmaceutical company Arexis AB

October 03, 2005

Biovitrum, a Swedish biotech company, acquires Arexis, a privately owned Swedish biotech and pharmaceuticals company, for an undisclosed consideration, from 3i Group Plc, Beijer Investors, Industrifonden, InnovationsKapital, and SEB Företagsinvest.

Vinge acted for Biovitrum AB.
Michael Wigge (responsible partner)
Niclas Bergström (associate)

Related

Vinge has advised AIP Management on the acquisition of the Överturingen wind farm

Vinge has advised AIP Management, an investor specialising in energy and climate transition infrastructure, in connection with the acquisition of an onshore wind farm in Överturingen in central Sweden.
October 22, 2026

Vinge advises Greenfood

 Vinge advises Greenfood in connection with the divestment of its Fresh Produce business to Dole.
October 21, 2026

Vinge has advised Investor in connection with acquisition of shares in EQT

 Vinge has advised Investor in connection with an acquisition of 12,500,000 shares in EQT AB from Wallenberg Investments for a total consideration of approximately SEK 3.5 billion.
October 19, 2026